arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Corvus Pharmaceuticals, Inc.

CRVS
$9.73 ▼ -0.86 (-8.07%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
47 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
43
Health
Weak
Bearish
auto_awesome

Analytical Summary

Corvus Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $898.7M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -6.8% ↘
FCF / Share $-0.17 ↘
Trailing P/E —
Price / Book 3.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

47-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-13.69M
— 0.0% —
FCF / Share Free cash flow per share
$-0.17
↓ -128.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑
25
Cash Quality ↑
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 12 years · 47 quarters